Is Ribociclib Calilon?

Ribociclib (Ribociclib) is Kaililong, which is the Chinese trade name of it marketed in China and other regions. Its pharmaceutical ingredients are basically the same as those of the original Ribociclib drug sold overseas. The trade name of Ribociclib sold overseas is Kisqali, which is available For the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor as initial endocrine therapy; or fulvestrant as initial endocrine-based therapy, or as part of endocrine therapy in postmenopausal women or men following disease progression.

The most common side effects of ribociclib in studies were decreased blood cell counts, primarily neutropenia, and anemia. Gastrointestinal disorders are also common, such as nausea and diarrhea, and hair loss. The drug also increases the QT interval and liver enzymes (alanine aminotransferase, aspartate aminotransferase). Ribociclib itself is a moderate to strong CYP3A4 inhibitor and therefore may increase concentrations of other drugs involved in this metabolism, such as midazolam. It also inhibits many transporters and therefore could theoretically interfere with the transport of other drugs in the body. It can also amplify the QT prolongation of other drugs such as antiarrhythmic drugs, clarithromycin, and haloperidol.

Due to the relatively short time on the market for the original drug Riboxil in China, its price and purchase methods are not yet known, and it has not yet been included in the scope of medical insurance. The price of the European version of Riboxil's original drug, 200mg*21 tablets, sold overseas may be more than RMB 20,000 per box, while the Indian version of Riboxil's original drug, 200mg*21 tablets, may be priced around RMB 3,000 per box (the price may fluctuate due to exchange rates). The ingredients of the two drugs are basically the same. There are currently no generic versions of Riboxil produced and marketed.